A detailed watercolor-style illustration of two large, irregularly shaped cells. The cells are primarily purple and pink, with dark, textured nuclei. They are surrounded by numerous fine, radiating lines and smaller, rounded structures, suggesting a complex biological environment. The background is a light, mottled yellow and white.

The Swedish Drug Development Pipeline 2015

AND AN OVERVIEW OF SWEDISH
R&D COMPANIES 2014

DECEMBER 2015

THIS REPORT IS PUBLISHED BY SWEDENBIO WITH SUPPORT FROM VINNOVA



swedenBIO

About the report

This report provides facts and figures about the current Swedish drug development pipeline for drugs intended for use in humans. The report serves as a quantitative indicator of the status and progress of the Swedish drug pipeline compounds, projects and their characteristics.

The projects that are analysed in depth have reached Phase I–III clinical development, and originate from a web-based survey and public information. Data and information is also presented from companies with projects in pre-clinical phase.

The report has been produced annually since 2006 and is published by SwedenBIO, the Swedish Life Science Industry Organization (www.swedenbio.se). Financial support has been obtained from Vinnova, the Swedish Governmental Agency for Innovation Systems (www.vinnova.se).

Contact information

Sara Gunnerås, PhD, Director of Research
sara.gunneras@swedenbio.se

Nicole Hanzon, MSc
nicole.hanzon@swedenbio.se

Material and method

A list of potentially relevant companies, with projects in pre-clinical and clinical stage was compiled. The list was based on the companies enclosed in last year's report, and supplemented with Swedish companies included in the database Biotech Gate (www.biotechgate.com). A search for companies in Swedish science parks and incubators was also done. Several companies were contacted directly in order to confirm on-going R&D activities. A more thorough investigation was done this year, which is why more companies were found, especially within the pre-clinical phase.

During October and November 2015, the companies on the list described above were invited to participate in a web based survey, about current pipeline status. Moreover, SwedenBIO recruited additional companies by informing about the survey in a newsletter and on the SwedenBIO website.

In total, 59 companies responded to the survey. For the remaining companies, pipeline information was collected from sources such as last year's report, company websites, www.clinicaltrial.gov and by e-mail and telephone interviews.

Corporate information, e.g. financial data from 2014, was obtained from Allabolag (www.allabolag.se).

Data from previous reports – The Swedish Drug Development Pipeline report -06, -07, -08, -09, -10, -11, -12, -13 and -14 were included for comparison. All reports may be downloaded from the SwedenBIO website: www.swedenbio.se/rapporter.

CONTENT

3 Introduction

5 Clinical Research Projects in 2015

- 5 Increased Number of Projects
- 6 Projects Accumulate in Phase II
- 7 Swedish Pipeline Strong in Oncology
- 8 Small Molecules Still Going Strong
- 9 Sweden Increasingly Popular for Clinical Trials
- 10 Orphan drugs on the rise

12 Drug Developing Companies in Sweden

- 13 Association with an Incubator or Science Park
- 14 Many Micro-sized Companies
- 15 A Virtual Company Structure
- 16 AstraZeneca's Drug Development Pipeline
- 16 Companies listed by Therapeutic Area

18 Lists of Included Companies

- 20 Top 10 List of Largest Companies by Number of Employees
- 21 Top 10 List of Largest Companies by Turnover
- 22 Companies A–Z
- 24 Companies Listed by Development Phase
- 26 Companies Listed by Therapeutic Areas

All illustrations are photos of aquarelles by Ina Schuppe Koistinen, find more on inasakvareller.se

Graphic design by Pär Ek, ekgrafiskform.se

INTRODUCTION

Optimistic companies push the Swedish drug development pipeline forward

The Swedish life science industry includes 1500 companies within pharma, biotech and medtech. Of these, around 800 are engaged in research and development programs in Sweden (Vinnova Analysis 2014:13).

This report highlights the approximately one hundred companies with Swedish headquarters that actively develop novel drugs. The report has been conducted annually since 2006 with the aim to map how the Swedish drug development pipeline evolves over time.

This year, 123 Swedish drug developing companies were identified, of which 58 have projects in clinical phase. The pipeline analysis presented in the report focuses on the companies that have projects in clinical phase I–III. You will also find an overview of the Swedish drug developing companies, including statistics on turnover, number of employees and company lists sorted by name, by therapeutic area and by development phase.

There are currently 107 projects in clinical development, which is an increase of 15 projects compared to last year. As in previous years, there is an accumulation of projects in phase II and this trend is now even stronger. The number of projects in phase I has increased and the number of projects in phase III has decreased. Of the

As in previous years, there is an accumulation of projects in phase II and this trend is now even stronger. The number of projects in phase I has increased and the number of projects in phase III has decreased. Of the phase III projects from last year, five have received positive results.

phase III projects from last year, five have received positive results.


Oncology and CNS are the therapy areas with most projects in clinical development.

There are now 38 oncology projects, which is an increase from 27 last year. There are 12 projects within CNS this year, compared to 9 projects last year.

Together, the 123 drug developing companies have around 1500 employees (based on data from 2014). However, almost 9 out of 10 companies are micro-sized businesses with 10 employees or less, and almost half of the companies have zero or one employees. These companies typically have a significant part of their R&D allocated to external consultants and specialized service providers.

This year, 59 of the 123 drug developing companies responded to our in depth web survey. To better understand the ecosystem around the drug developing companies, we asked companies about the ratio between employees and consultants. Within R&D, the 59 companies together employ almost as many consultants as internal R&D employees. For the first time, the survey also included questions about expectations for the coming three years. Of the 59 respondents, 43 companies said that they will add employees, increase their use of consultants, or both.


Clinical Research Projects in 2015



INCREASED NUMBER OF PROJECTS

This year's pipeline report includes 58 companies covering a total of 107 projects in Phase I–Phase III clinical trials. This is an increase from 56 companies with 91 projects in clinical trials that were included in last year's report.

In the current pipeline, 74 of the 107 projects are unique entities, including both small molecules and biopharmaceuticals. An entity can typically be tested for more than one indication. In this year's report, 22 entities are being tested for more than one indication.



Source: web based survey, public databases, company webpages and company interviews.

PROJECTS ACCUMULATE IN PHASE II

This year, the numbers of projects in the respective phases are reported as being 30 projects in Phase I, 70 in Phase II and 7 in Phase III.

Compared to last year, there has been a substantial increase in the number of Phase I projects (+9), but a decrease in the number of Phase III projects (–6). As in previous years, the large majority of the projects are found to be in Phase II, and this number has increased from 55 to 70 projects (+15).

Since last year's report, 28 projects have changed status, either from pre-clinical to clinical phase, or moved on to the next clinical phase, indicating good overall progress in the Swedish drug development pipeline.


Seven Phase III projects

Last year 13 projects were reported to be in Phase III. Three of those remain in Phase III, five

have generated negative results or changed their focus, five have received positive results. During 2015, four new projects entered Phase III.

Projects reaching the market

Oasmia's lead cancer product, Paclical, has received market approval in the Russian Federation. Recently EMA approved SOBI's Xiapex for concurrent treatment of palpable cords, Orfadin was approved in Japan for the treatment of hereditary tyrosinaemia type-1 and Cometriq was approved in Europe for the treatment of progressive, unresectable, locally advanced or metastatic medullary thyroid carcinoma.



Source: web based survey, public databases, company webpages and company interviews.

SWEDISH PIPELINE STRONG IN ONCOLOGY

Oncology is one of the largest therapeutic areas in terms of drug development activity globally, addressing a disease area that causes more deaths than all other diseases put together, with the exclusion of cardiovascular diseases.

The Swedish drug development pipeline is dominated by oncology projects, counting 38 projects. This is an increase from 27 last year, with large jumps both in the number of Phase I and Phase II studies. Another strong area is CNS with 12 projects, compared with 9 projects last year. The category "Other" includes projects in the areas of immunology, endocrinology, inflammation, etc.

38

Oncology

21

Other

12

CNS

5

Pain

7

Diabetic/
Metabolism

6

Gastro-
intestinal

5

Transplantation

5

Cardiovascular

4

Dermatology


4

Infection

SMALL MOLECULES STILL GOING STRONG

Similarly to last year, small molecules comprise the majority of the projects in the pipeline, even though large molecules still represent 38% of the projects. The last years have been stable in terms of the distribution between large and small molecules, with the distribution staying at the same level as 2014. This year 44 of the 74 compounds are small molecules, and 30 are large molecules.


The group of large molecules includes: antibodies, therapeutic vaccines, cell therapies, hormones and in this category also including the hybrid class of peptides.



Source: web based survey, public databases, company webpages and company interviews.

SWEDEN INCREASINGLY POPULAR FOR CLINICAL TRIALS

This year a higher number of clinical trials were conducted in Sweden, or partly in Sweden, compared to last year. Of 97 clinical trials, 40% were performed in Sweden only and an additional 28% in Sweden and abroad. This is an increase from the previous year when 53% of the clinical trials were conducted in Sweden only or in Sweden and abroad.



Source: web based survey, public databases, company webpages and company interviews.
This graph shows data from the 97 out of 107 projects where location for clinical trials could be found.

ORPHAN DRUGS ON THE RISE


Global trend

Developing a treatment for a rare disease has become increasingly popular, and a record 290 and 196 orphan drug designations were granted in the US and EU respectively in 2014.

Although a rare disease only affects 5 out of 10,000 persons or less according to EU definition, the market share for orphan drugs is expected to account for 19% of the total share of prescription drug sales in 2020 excluding generics, reaching \$176 billion in worldwide annual

sales (Orphan Drug Report 2014, EvaluatePharma).

To get orphan designation in the EU, the medicine has to be developed for the diagnosis, prevention or treatment of rare diseases that are life-threatening or chronically debilitating. About 30 million people living in the European Union suffer from a rare disease (EMA). The indication with most filed orphan drug designations in EU is Non-Hodgkin Lymphoma (Orphan Drug Report 2014, EvaluatePharma).



Source: EMA, FDA, company web pages and Orphan Drug Report 2014, EvaluatePharma.

Swedish companies


According to the drug development pipeline survey 2015, 42 of the projects in Phase I–III target an orphan indication. This is almost double the number of the 22 projects reported in 2014.

Since 2000, 60 orphan drug status designations have been granted in total to Swedish companies by the EMA and FDA. In 2014, seven Swedish companies received orphan drug designations granted by EMA and/or FDA:

- **A1M Pharma:** use of recombinant human alpha-1-microglobulin for treatment of pre-eclampsia.
- **Active Biotech:** use of quinolin substance for treatment of systemic sclerosis.
- **Aprea:** use of agent targeting p53 activity for treatment of ovarian cancer.
- **Clanotech:** use of anti-fibrotic and anti-angiogenic substance for prevention of scarring post glaucoma filtration surgery.


- **Corline Biomedical:** use of macromolecular conjugate of heparin sodium on a polymer backbone for prevention of ischaemia reperfusion injury associated with solid organ transplantation.
- **iCell Science:** use of ex-vivo-cultured human mesenchymal stromal cells for prevention of graft rejection following solid organ transplantation.
- **OxThera:** use of oxalobacter formigenes strain HC-1 for treatment of short bowel syndrome.

Note that Vivolux got orphan designation status from FDA in 2014 for the treatment of multiple myeloma, but moved its HQ to USA in the same year and is not included in this report.




Source: EMA, FDA, company web pages and Orphan Drug Report 2014, EvaluatePharma.

Drug Developing Companies in Sweden



ASSOCIATION WITH AN INCUBATOR OR SCIENCE PARK

The Swedish drug developing companies are centred in four geographical regions. The majority of the companies (57%) is located in the Stockholm-Uppsala region, followed by the Malmö-Lund region (24%), Gothenburg (14%) and Umeå (5%). More than half of the companies are associated with an incubator or science park. Karolinska Institutet Science Park in Stockholm, Medicon Village in Lund and Sahlgrenska Science Park in Gothenburg are the three major science parks. The incubators with most Swedish biotech and pharmaceutical companies are Lund Life Science Incubator, GU Ventures in Gothenburg and Uppsala Innovation Centre. Some companies are connected to more than one incubator or science park. Note that the incubators, for example, in the Umeå region, also host numerous research projects, but these are excluded from this report since they are not yet incorporated.



Source: web based survey, public databases, company webpages and company interviews.
Location was retrieved from Allabolag.se, based on company information from December 31, 2014.

MANY MICRO-SIZED COMPANIES

A total of 123 Swedish biotech and pharmaceutical companies with their head office in Sweden have been identified to be actively working with drug development. The company information was retrieved from the 2014 annual reports. Companies founded in 2015, are not included in the analysis, and will be listed in next year's report.

Together, the companies in this analysis have about 1500 employees on their payrolls in 2014 – that is 100 more than in 2013. Swedish Orphan Biovitrum, with 589 employees, is currently the only large research company in Sweden*.

Most companies, representing 88 % of those listed,


are micro-sized companies with 10 or fewer employees. Almost half of them (48%) have only 0–1 employees. The micro-sized companies add up to a 108 in total and employ 276 persons. Many of the micro-sized companies are so called “virtual companies”, meaning that they have few employees in-house and a significant part of their R&D allocated to external consultants and specialized service providers.

* Since AstraZeneca's HQ is located in UK, they are not included in this report.

Number of
companies

Company
size


Employees



Source: web based survey, public databases, company webpages and company interviews.
The data about the size and turnover is based on annual reports from 2014.


A VIRTUAL COMPANY STRUCTURE

The **59 companies** that responded to this years survey have a combined workforce of 1160 employees. In addition, they engage 627 consultants or contractors counted as Full Time Equivalents (FTE). Within the R&D-functions of these companies, the ratio of consultants versus employees is high with the number of consultants almost matching the number of regular R&D employees (398 vs 445).




OPTIMISTIC OUTLOOK FOR THE FUTURE

The **majority** of the 59 companies that responded to this years survey stated that they intend to increase their workforce throughout the next three years. This optimism spans all sizes of companies and 43 out of 59 companies want to increase the number of regular employees or the number of consultants. As many as 26 companies plan to increase both the number of consultants and the number of employees. Only one company is planning to decrease its workforce.



Source: Web based survey.

AstraZeneca's drug development pipeline



ABOUT ASTRAZENECA

AstraZeneca is currently the only global pharmaceutical company with R&D function in Sweden. The company is not included in the analysis of the report since the HQ was placed in UK after the merger of Swedish Astra and British Zeneca in 1999. Nevertheless, the company has a strong presence in Sweden, and employs 6 200 people (end of 2014) working in research, manufacturing and marketing. AstraZeneca has three global strategic research sites worldwide, one of which is located in Mölndal, Gothenburg. The Gothenburg R&D site has 2 400 employees and almost 25 percent of the global 4,941 MUSD R&D investment was made in Sweden (2014).

AstraZeneca is engaged in Swedish academic research through several joint-research collaborations. The Karolinska Institutet/AstraZeneca Integrated Cardio Metabolic Centre was initiated 2013. It is AstraZeneca's most extensive contract with an academic institution through history. During the five-year initial contract period, AstraZeneca will contribute up to USD 100 million. The centre has nine open, integrated and collaborating research groups with a focus on both pre-clinical and clinical studies.

In the fall of 2015, AstraZeneca, the University of Gothenburg and Chalmers University of Technology entered into a new collaboration on advanced mass spectrometry equipment. In this way, industry and institutions jointly engage in ground-breaking research.


In May 2015, the company announced that a 285 million USD investment is to be made in a new high-technology facility for the manufacture of biopharmaceuticals. It will be located in Gärtuna, strategically chosen for its proximity to the site in Södertälje, which is one of the largest production sites for pharmaceuticals worldwide. The new facility will focus on filling and packaging of biopharmaceuticals, and is expected to deliver drugs to the company's clinical trial programs from the end of 2018.

ASTRAZENECA'S DRUG DEVELOPMENT PIPELINE

Globally, AstraZeneca reported 118 projects in Phase I–III by the end of 2014. This is an increase of 33 projects compared to last year when 85 projects were reported. In addition, 16 projects were approved or launched. Most projects are within AstraZeneca's three strategic therapeutic areas: cardiovascular and metabolic diseases, oncology, and respiratory, inflammation and autoimmunity. AstraZeneca reported an additional 26 products in clinical trials that are line extensions. During 2014, nine projects were discontinued and 50 projects successfully progressed to their next phase. 16 projects were approved or launched.

In this report, we have chosen to make a comparison between AstraZeneca's and Sweden's pipeline. Interestingly, the size of the Swedish research companies' portfolio corresponds to a global pharma company's portfolio, but the distribution of projects between Phase I–III is different.

AstraZeneca's global pipeline has a 50-50 balance of small and large molecules, and approximately 30 large molecules are under clinical development. This is a similar result to the projects analysed from the 59 companies in clinical phase in this report, showing a 40-60 balance, with 30 large and 44 small molecules all together in the Swedish pipeline.



Source: Data was obtained from AstraZeneca's web page and the annual report presenting the pipeline status of 2014. Note that AstraZeneca does not divide its research portfolio in different national platforms. Phase III projects also include projects ready for registration.

Lists of Included Companies





Eight new companies, registered in 2014

Aptahem	Developing new effective antiplatelet drugs for treating and preventing diseases caused by blockage of blood vessels, such as heart attack or stroke.
Double Bond Pharmaceutical International	Developing first-in-class approaches for treatment of cancers, infections, autoimmune diseases and other life-threatening disorders.
Elastomics	Developing first-in-class medicines for liver and pulmonary fibrosis. Spin-off and fully owned subsidiary of YO Proteins.
Emeriti Pharma	Early drug discovery is done in the field of prodrugs, especially related to drugs on the market.
Gabather	Developing novel drugs to treat several diseases originating in the central nervous system (CNS). Key targeted diseases include anxiety, pain, and Alzheimers disease.
Glionova Therapeutics	Developing new therapies for cancer (glioblastoma).
GotImmune	Developing therapeutic products for the treatment of Helicobacter pylori.
Karessa Pharma	Developing products with clear competitive advantages in the therapeutic area of erectile dysfunction.

Source: Registration year was retrieved from allabolag.se.



Top 10 list of largest companies by number of employees

COMPANY	FTE 2014 (FTE 2013)	HEAD OFFICE	THERAPEUTIC AREA	OWNER	FOUNDED	TURNOVER 2014 (TSEK)
Swedish Orphan Biovitrum	589 (546)	Stockholm	Rare diseases: inflammation, genetics & metabolism.	Public	1939	2 646 873
Medivir	141 (153)	Stockholm	Infectious diseases: hepatitis C.	Public	1987	1 782 212
Orexo	111 (106)	Uppsala	Specialty pharma and drug delivery technology.	Public	1994	608 876
Oasmia Pharmaceutical	74 (72)	Uppsala	Nanoparticle formulations and drug-delivery systems based on well-established cytostatics	Public	1988	33 978
Active Biotech	58 (61)	Lund	Immunology: multiple sclerosis and cancer.	Public	1983	10 399
Karo Bio	39 (40)	Stockholm	Nuclear receptors: neuropsychiatry, inflammation, autoimmune diseases and cancer.	Public	1987	30 152
Camurus	38 (35)	Lund	Drug-delivery systems for development of high-value therapeutics.	Public	2004	210 463
BioInvent International	38 (47)	Lund	Antibody therapeutics: treatment of cancer.	Public	1997	50 468
Alligator Bioscience	28 (24)	Lund	Tumor targeted immuno-oncology.	Public	2000	49 671
Bioarctic Neuroscience	27 (28)	Stockholm	Neurodegenerative diseases (alzheimer).	Private	2000	55 291

Top 10 list of largest companies by turnover

COMPANY	TURNOVER 2014 (TSEK) (TURNOVER 2013)	HEAD OFFICE	THERAPEUTIC AREA	OWNER	FOUNDED	FTE 2014
Swedish Orphan Biovitrum	2 646 873 (2 200 318)	Stockholm	Rare diseases (inflammation, genetics & metabolism)	Public	1939	589
Medivir	1 782 212 (452 493)	Stockholm	Infectious diseases (hepatitis C)	Public	1987	141
Orexo	608 876 (447 019)	Uppsala	Specialty pharma and drug delivery technology	Public	1995	111
Camurus	210 463 (203 066)	Lund	Drug-delivery systems	Public	2004	38
Moberg Pharma	205 971 (158 457)	Stockholm	Skin diseases	Public	2006	18
Affibody Medical	57 623 (67 694)	Stockholm	Next generation biopharmaceuticals based on its technology platforms.	Public	2004	23
Bioarctic Neuroscience	55 291 (58 752)	Stockholm	Neurodegenerative diseases (alzheimer)	Private	2000	27
Biolnvent Bioscience	50 468 (82 651)	Lund	Antibody therapeutics: treatment of cancer.	Public	1997	38
Alligator Bioscience	49 671 (23 392)	Lund	Tumor targeted immuno-oncology.	Public	2000	28
InDex Pharmaceuticals	45 160 (499)	Stockholm	Inflammatory and immunological diseases (Ulcerative colitis)	Private	2006	7

Source: Public databases, company webpages and allabolag.se.

Companies A–Z

A1M Pharma

Abera Bioscience

Active Biotech

AcuCort

Adenovir Pharma

Affibody Medical

Akinion Pharmaceuticals

Albireo

Alligator Bioscience

AlzeCure Foundation

Alzinova

Anamar

Apodemus

Aprea

Aptahem

Athera Biotechnologies

Axcentua Pharmaceuticals

Axelar

Beactica

Betagenon

Bioarctic Neuroscience

Biocrine

Biognos

Bioimics

BioInvent International

Camurus

Canimguide Therapeutics

Canqura Oncology

Cantargia

Cebix

Cellprotect Nordic Pharmaceuticals

Cereno Scientific

ClanoTech

Corline Biomedical

Cormorant Pharmaceuticals

DanPET

Dextech Medical

Diamyd Medical

Dilafor

Dilaforette

Double Bond Pharmaceutical International

Elastomics

Emeriti Pharma

Empros Pharma

Eribis Pharmaceuticals

Eurocine Vaccines

Follicum

Gabather

Galecto Biotech

Glactone Pharma

Glionova

Glucox Biotech

GotImmune

Grespo

Hansa Medical

Helicure

iCell Science

Idogen

Immun System I.M.S.


ImmuneBiotech

Immunicum

InDex Pharmaceuticals

Infant Bacterial Therapeutics

Integrative Research Laboratories Sweden



Companies A–Z

Isifer

IsletOne

Isofol Medical

Kancera

Karessa Pharma

Karo Bio

LIDDS

Lipidor

Lipigon Pharmaceuticals

Medivir

Moberg Pharma

Molecules of Man

Nares

NeuroVive Pharmaceutical

Northern Light Pharmaceuticals

NovaSaid

Noviga Research

Oasmia Pharmaceutical

Omnia Healer

Oncopeptides

Oncorena

Orexo

OxThera

Parkcell

Peptonic Medical

Pergamum

Pharmalink

Pharmalundensis

Pharmanest

PharmNovo

PledPharma

ProNoxis

QuiaPEG Pharmaceuticals

Red Glead Discovery

Redoxis

Redwood pharma

Respiratorius

RPSP Phamra

Scandinavian Biopharma

Sixera Pharma

Spago Nanomedical

Sprint Bioscience

Strongbone

Strongbridge Biopharma

Swecure

Swedish Orphan Biovitrum

Synphora

TikoMed

Toleranzia

Umecrine

Umecrine Cognition

Umecrine Mood

Vicore Pharma

Viscogel

Wilson Therapeutics

WntResearch

XImmune

Xintela

Xspray Microparticles

List of 123 companies that actively develop novel drugs in Sweden. Based on company information from December 31, 2014.

Companies listed by development phase

PHASE I

Active Biotech	Other
Alligator Bioscience	Oncology
AnaMar	Inflammation
Aprea	Oncology
Aprea	Oncology
Athera Biotechnologies	Cardiovascular
Athera Biotechnologies	Cardiovascular
Betagenon	Diabetic/Metabolism
Betagenon	Cardiovascular
BioArctic Neuroscience	CNS
BiolInvent	Infection
BiolInvent	Oncology
BiolInvent	Oncology
BiolInvent	Oncology
CellProtect Nordic Pharma.	Oncology
Cormorant Pharmaceuticals	Oncology
Cormorant Pharmaceuticals	Oncology
Cormorant Pharmaceuticals	Oncology
Diamyd Medical	Diabetic/Metabolism
iCell Science	Transplantation
Immunicum	Oncology
Integrative Research Lab.	CNS
Integrative Research Lab.	CNS
Integrative Research Lab.	CNS
Integrative Research Lab.	CNS
Oasmia	Oncology
Oasmia	Oncology
Pergamum	Dermatology
WntResearch	Oncology
Xspray	Oncology

PHASE II

Active Biotech	CNS
Active Biotech	Other
Active Biotech	Oncology
Active Biotech	Oncology
Active Biotech	Oncology
Adenovir	Other
Affibody	Oncology
Akinion	Oncology
Albireo	Gastro-Intestinal
Albireo	Gastro-intestinal
Albireo	Gastro-intestinal
Albireo	Gastro-intestinal
Apodemus	CNS
Axcentua	Oncology
Axelar	Oncology
Axelar	Oncology
BioArctic Neuroscience	CNS
BiolInvent	Oncology
BiolInvent	Oncology
Camurus	Endocrinology
Camurus	Oncology
Camurus	Oncology
Camurus	Pain
Dextech Medical	Oncology
Dextech Medical	Endocrinology
Dextech Medical	Oncology
Diamyd Medical	Diabetic/Metabolism
Diamyd Medical	Diabetic/Metabolism
Diamyd Medical	Diabetic/Metabolism
Dilafor	Other
Dilaforette	Infection
Dilaforette	Infection
Galecto Biotech	Other
Hansa Medical	Transplantation
Hansa Medical	Transplantation
Immunicum	Oncology

Companies listed by development phase

PHASE II CONTINUING

InDex Pharmaceuticals	Gastro-Intestinal
Infant Bacterial Therapeutics	Gastro-Intestinal
Isifer	Immunology
Isifer	Other
IsletOne	Inflammation
IsletOne	Transplantation
Isofol	Oncology
Isofol	Oncology
Isofol	Oncology
LIDDS	Oncology
Medivir	Other
Moberg Pharma	Pain
NeuroVive Pharmaceutical	Cardiovascular
NeuroVive Pharmaceutical	CNS
Oncopeptides	Oncology
Orexo	Pain
OxThera Intellectual Property	Other
Peptonic Medical	Other
Pergamum	Dermatology
Pergamum	Dermatology
Pergamum	Dermatology
Pharmalink	Other
Pharmalink	Transplantation
Pharmalundensis	Other
Pharmanest	Pain
PledPharma	Oncology
PledPharma	Cardiovascular
Redwood Pharma	Other
Respiratorius	Oncology
RSPR Pharma	Inflammation
Scandinavian Biopharma	Infection
Synphora	Pain
TikoMed	Diabetic/Metabolism
Umecrine Mood	CNS

PHASE III

Active Biotech	CNS
Camurus	CNS
Double Bond Pharmaceutical	Oncology
Immunsystem IMS	Other
OxThera Intellectual Property	Diabetic/Metabolism
Swedish Orphan Biovitrum	Other
Swedish Orphan Biovitrum	Other

Companies listed by therapeutic areas

CARDIOVASCULAR

Athera Biotechnologies
Betagenon
NeuroVive Pharmaceutical
PledPharma

CNS

Active Biotech
Apodemus
BioArctic Neuroscience
Camurus
Integrative Research Laboratories
NeuroVive Pharmaceutical
Umeocrine Mood

DERMATOLOGY

Pergamum

DIABETIC/METABOLISM

Betagenon
Diamyd Medical
OxThera Intellectual Property
TikoMed

ENDOCRINOLOGY

Camurus
Dextech Medical

GASTRO-INTESTINAL

Albireo
InDex Pharmaceuticals
Infant Bacterial Therapeutics

IMMUNOLOGY

Isifer

INFECTION

BiolInvent
Dilaforette
Scandinavian Biopharma

INFLAMMATION

AnaMar
IsletOne
RSPR Pharma

ONCOLOGY

Active Biotech
Affibody
Akinion
Alligator Bioscience
Aprea
Axcentua
Axelar
BiolInvent
Camurus
CellProtect Nordic Pharmaceuticals
Cormorant Pharmaceuticals
Dextech Medical
Double Bond Pharmaceutical
Immunicum
Isofol
LIDDS
Oasmia
Oncopeptides
PledPharma
Respiratorius
WntResearch
Xspray

PAIN

Camurus
Moberg Pharma
Orexo
Pharmanest
Synphora

TRANSPLANTATION

Hansa Medical
iCell Science
IsletOne
Pharmalink

OTHER

Active Biotech
Adenovir
Dilafor
Galecto Biotech
Immunsystem IMS
Isifer
Medivir
OxThera Intellectual Property
Peptonic Medical
Pharmalink
Pharmalundensis
Redwood Pharma
Swedish Orphan Biovitrum



Increased number of projects in clinical development

The Swedish life science industry includes 1500 companies within pharma, biotech and medtech. Of these, around 800 are engaged in research and development programs in Sweden.

This report highlights the 123 identified companies with Swedish headquarters that actively develop novel drugs. Included you will find an overview of those companies, with statistics on turnover, number of employees and company lists sorted by name, by therapeutic area and by development phase. The pipeline analysis presented in the report focuses on the 58 companies that have projects in clinical phase I–III.

Key findings in the 2014 report include:

- ▶ There are currently 107 projects in clinical development, which is an increase of 15 projects compared to last year.
- ▶ Oncology and CNS are the therapy areas with most projects in clinical development.
- ▶ A higher number of clinical trials were conducted in Sweden compared to last year.
- ▶ 42 of the projects in Phase I–III target an orphan indication. This is almost double the number of the 22 projects reported in 2014.
- ▶ Almost 9 out of 10 companies are micro-sized businesses with 10 employees or less. These companies typically have a significant part of their R&D allocated to external consultants and specialized service providers.

ILLUSTRATION: INASAKVARELLER.SE

The report has been published annually since 2006 and is compiled by SwedenBIO, the Swedish Life Science Industry Organization (www.swedenbio.se). Financial support has been obtained from VINNOVA, the Swedish Governmental Agency for Innovation Systems (www.vinnova.se).

